UPLOAD Filing
Aspire Biopharma Holdings, Inc.
Date: Feb. 24, 2026 · CIK: 0001847345 · Accession: 0000000000-26-001916
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293515
Letter
February 24, 2026 Ernest J. Scheidemann Chief Financial Officer Aspire Biopharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Estero, Florida 33928 Re:Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed February 17, 2026 File No. 333-293515 Dear Ernest J. Scheidemann: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Arthur S. Marcus, Esq.
Show Raw Text
February 24, 2026
Ernest J. Scheidemann
Chief Financial Officer
Aspire Biopharma Holdings, Inc.
23150 Fashion Drive, Suite 232
Estero, Florida 33928
Re:Aspire Biopharma Holdings, Inc.
Registration Statement on Form S-1
Filed February 17, 2026
File No. 333-293515
Dear Ernest J. Scheidemann:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Arthur S. Marcus, Esq.